ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 075,68
0,99%
Dow Jones
38 863,72
0,03%
DAX
18 430,05
1,42%
Brent Oil
83,085
-0,47%
Bitcoin
63 169,29
0,00%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Candel Therapeutics Inc (CADL)

  7. Candel Therapeutics Inc (CADL) Actualités

CADL Candel Therapeutics Inc

9,35
0,50 (5,65%)
Dernière mise à jour : 20:14:54
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Candel Therapeutics Inc CADL NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,50 5,65% 9,35 20:14:54
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
9,00 8,66 9,6299 8,85
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
25/4/202414:00GLOBECandel Therapeutics Announces Upcoming Presentations at the..
11/4/202415:00GLOBECandel Therapeutics Receives FDA Orphan Drug Designation for..
09/4/202414:00GLOBECandel Therapeutics Presents Preclinical Data at AACR on..
04/4/202414:00GLOBECandel Therapeutics Announces Positive Interim Data from..
28/3/202421:05GLOBECandel Therapeutics Announces Oral Presentation During the..
28/3/202413:05GLOBECandel Therapeutics Reports Fourth Quarter and Full Year..
06/3/202414:00EDGAR2Form 8-K - Current report
05/3/202422:30GLOBECandel Therapeutics Announces an Upcoming Presentation at..
13/2/202415:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/2/202413:45EDGAR2Form 8-K - Current report
13/2/202413:30GLOBECAN-3110 Receives FDA Fast Track Designation for Treatment..
05/2/202414:00GLOBECandel Therapeutics Sets Path to Success: Recent..
19/1/202414:30EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/1/202422:30EDGAR2Form 8-K - Current report
03/1/202414:30EDGAR2Form 8-K - Current report
12/12/202314:58DJNCandel Therapeutics Shares Soar After FDA Fast Track of..
12/12/202314:30EDGAR2Form 8-K - Current report
12/12/202314:00GLOBECandel Therapeutics Receives FDA Fast Track Designation for..
30/11/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:00EDGAR2Form 8-K - Current report
28/11/202315:00GLOBECandel Therapeutics Announces Restructuring to Prioritize..
21/11/202323:00EDGAR2Form 8-K - Current report
09/11/202314:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202314:16EDGAR2Form 8-K - Current report
09/11/202314:00GLOBECandel Therapeutics Reports Third Quarter 2023 Financial..
06/11/202314:53EDGAR2Form 8-K - Current report
06/11/202314:15EDGAR2Form 8-K - Current report
04/11/202313:00GLOBECandel Therapeutics Presents Preclinical Data from its..
03/11/202317:00GLOBECandel Therapeutics Announces Initial Positive Interim Data..
18/10/202317:31EDGAR2Form 8-K - Current report
18/10/202317:00GLOBECandel Therapeutics Announces Nature Publication Showing..
27/9/202315:40GLOBECandel Therapeutics Announces Three Abstracts Accepted for..
26/9/202314:30EDGAR2Form 8-K - Current report
26/9/202314:00GLOBECandel Therapeutics Reports Encouraging Initial Survival..
06/9/202314:00GLOBECandel Therapeutics to Participate in the H.C. Wainwright..
10/8/202314:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202314:15EDGAR2Form 8-K - Current report
10/8/202314:00GLOBECandel Therapeutics Reports Second Quarter 2023 Financial..
02/8/202314:00GLOBECandel Therapeutics to Participate in the Canaccord Genuity..
29/6/202315:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202315:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202315:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202314:31EDGAR2Form 8-K - Current report
13/6/202314:00GLOBECandel Therapeutics Announces It Expects to Report Topline..
08/6/202314:00GLOBECandel Therapeutics Appoints Experienced Manufacturing..

Dernières Valeurs Consultées

NASDAQ
CADL
Candel Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés